Diabetic Dyslipidemia
PPAR α/γ AGONISTS: A NEWER APPROACH TO DIABETIC DYSLIPIDEMIA
... fourth diabetic in the world is an Indian. Incidence of dyslipidemia among people suffering from diabetes is shooting up each year around the ...Atherogenic diabetic dyslipidemia (ADD) is an ...
17
Saroglitazar: India's Answer to Diabetic Dyslipidemia
... Saroglitazar is indicated for the treat- ment of diabetic dyslipidemia and hypertri- glyceridemia with diabetes mellitus type-2 not controlled by statins therapy. Clinical studies have demonstrated ...
8
The Effect of Biochanin A as PPAR γ agonist on LDL Particles Diameter and Type 2 Diabetic Dyslipidemia
... in diabetic dyslipidemia ...anti- diabetic mechanisms that have been explained in different studies are the result of stimulation of insulin secretion from beta pancreatic cells, insulin mimetic ...
8
Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia – A Review
... associated dyslipidemia adds to the lethality of type 2 diabetes mellitus and requires newer and better treatment ...words: Diabetic dyslipidemia, Glitazars, PPAR agonists, Type 2 ...
5
Control of Diabetic Dyslipidemia among Type II Diabetics in Western Region of the Republic of Macedonia
... of dyslipidemia among T2DM patients, in the western region of the Republic of Macedonia,continue to be alarmingly low, particularly in ...with diabetic dyslipidemia, are not achieving the LDL-C goal ...
8
Apolipoprotein E in diabetic dyslipidemia and atherosclerosis
... severe diabetic dyslipidemia at both ends of the LDLR spectrum; LDLR deficiency in Chapter 2 and increased LDLR expression in Chapter ...of diabetic dyslipidemia and ...
197
Quantitative Estimation of Gallic Acid as Biomarker in Lipitame Tablets by HPTLC Densitometry for Diabetic Dyslipidemia
... Standardization of specific biologically active gallic acid component was identified as material in the poly herbal formulation and quantitative analysis cover identification of chemical components where as quantitative ...
10
ZYGOPHYLLUM GAETULUM AQUEOUS EXTRACT PROTECTS AGAINST DIABETIC DYSLIPIDEMIA AND ATTENUATES LIVER AND KIDNEY OXIDATIVE DAMAGE IN STREPTOZOTOCIN INDUCED DIABETIC RATS
... bw). Diabetic rats (n=12), weighing 263±5g, were randomly divided into two groups fed a casein diet supplemented or not with Zg extract (1g/kg bw), for 4 ...untreated diabetic rats, glycemia and HOMA-IR ...
9
Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study
... with dyslipidemia must be interpreted with caution, and further larger studies in people with dyslipidemia are ...the diabetic dyslipidemia was defined in a data-driven manner, however the ...
9
Factors Predicting Dyslipidemia in Obese Type 2 Diabetic Subjects
... of dyslipidemia among obese type 2 diabetics and to determine the associated factors predicting dyslipidemia in these ...subjects. Diabetic dyslipidemia is a major risk factor for ...
6
Dyslipidemia in diabetic nephropathy
... that dyslipidemia is frequently complicated with ...Recently, dyslipidemia has been recognized to be involved in the progression of ...general, diabetic dyslipidemia is caused by impaired ...
9
Dyslipidemia and associated factors among diabetic patients attending Durame General Hospital in Southern Nations, Nationalities, and People’s Region
... HDL-C. Diabetic dyslipidemia is a cluster of plasma lipid and lipoprotein abnormality that is metabolically interrelated, and it is characterized by low HDL-C and increased LDL-C, TGs, and total cholesterol ...
7
A Study of Coronary Risk and LDL in Type II Diabetic Patients
... Even at concentrations well below the National Cholesterol Education Program target of 130 mg/dl, LDL cholesterol is a strong independent predictor of coronary heart disease in individuals with diabetes, even when ...
8
Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Zücker rats
... studying diabetic ZDF, Coimbra et ...became diabetic after 14 weeks of ...in diabetic fa/fa rats after ...of diabetic nephropathy as is the case in diabetic ...
9
Prevalence of dyslipidemia associated with complications in diabetic patients: a nationwide study in Thailand
... and dyslipidemia in Thai T2DM pa- ...between dyslipidemia and ...of dyslipidemia and microalbumi- nuria with the risk of cardiovascular and kidney compli- cations in diabetic patients ...
8
EFFECT OF INSULIN VERSES METFORMIN ON HYPERGLYCEMIA AND DYSLIPIDEMIA IN TYPE-II DIABETIC PATIENTS
... Furthermore, dyslipidemia was more severe in female diabetic group as compare to male diabetic group, might be because of high fatty diet, less physi- cal activities and poor health management in ...
5
Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence
... patients spread over a meaningful clinical range for the variables under study [19]. As the majority of T1DM are normolipaemic, combining T1DM and T2DM patients with significant differences in both non-HDL-C and apoB, as ...
7
Esculin improves dyslipidemia, inflammation and renal damage in streptozotocin induced diabetic rats
... of diabetic nephropathy ...for diabetic complications ...in diabetic rats, it was significantly ...STZ-induced diabetic rats, which was correlated with renal ...the diabetic nephropathy ...
8
Comparative study of Dyslipidemia in Diabetic patients with Diabetic Nephropathy and Diabetic patients without Nephropathy
... of dyslipidemia in the development of diabetic nephropathy and the impotance of lipid-lowering therapy to prevent the cardiovascular disease and diabetic ...
6
PILOT STUDY Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia
... in diabetic patients. Most of the type 2 diabetic patients are overweight and obese at the time of diagnosis and most of them have low compliance with drugs and diet as compared to non-obese ...
5